Novartis will acquire Avidity Biosciences in a newly announced definitive merger agreement. The news follows the separation ...
Novartis plans to acquire Avidity Biosciences to add RNA therapeutics to its neuroscience biz to target rare genetic ...
According to the agreement, Avidity ( NASDAQ: RNA) shareholders will receive $72 a share in cash, a 46% premium to Friday’s ...
An update from PYC Therapeutics Limited ( ($AU:PYC) ) is now available. PYC Therapeutics Limited announced significant progress in its drug ...
Learn more about whether AbbVie Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity ...
Novartis has agreed to acquire Avidity Biosciences, a San Diego-based biopharmaceutical company developing therapies for rare ...
Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.
The Swiss drugmaker on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash ...
Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback